Trial Profile
A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs RBX 2660 (Primary)
- Indications Clostridium difficile infections
- Focus Registrational; Therapeutic Use
- Acronyms PUNCHCD3
- Sponsors Rebiotix
- 23 Oct 2023 Ad hoc analysis results presented in a Ferring Pharmaceuticals media release.
- 23 Oct 2023 According to a Ferring Pharmaceuticals media release, the poster of ad hoc analysis were presented at the American College of Gastroenterology's (ACG) 2023 Annual Scientific Meeting.
- 11 Oct 2023 According to a Ferring Pharmaceuticals media release, company announced four poster presentations at Infectious Disease Week (IDWeek) 2023 for REBYOTA.